Abstract:To evaluate the clinical practice pattern of adjuvant vaginal brachytherapy (VBT) in early-stage endometrial carcinoma (EC) according to ESMO-ESGO-ESTRO risk classification in China from long-term updated data of a multi-institutional analysis. We retrospectively evaluated clinical data of patients with early-stage EC at 13 institutions in China between 2000 and 2015. Eligibility requirements included the primary hysterectomy/bilateral salpingo-oophorectomy and adjuvant radiotherapy, stage I and II disease (FIGO 2009 staging), and complete clinicopathologic and follow-up information. All patients were divided into low-risk (LR), intermediate-risk (IR), high-intermediate risk (HIR) and high-risk (HR) groups according to ESMO-ESGO-ESTRO risk classification. We evaluated clinical practice pattern and tendency of VBT in different risk groups during various periods. Proportions were compared by using the Chi square test for values of 5 or higher and with Fisher’s exact test for values of less than 5. All data were examined using statistical analysis software. A total of 1268 early-stage patients were reviewed and 1108 cases with intact data were included in the analysis. The median follow-up time was 53 months (range 6–207 months). The median age was 56 years (range 23–86 years). Stage Ia/b disease represented 86.0% of the cohort, HR patients 22.9%, HIR patients 20.0%, IR patients 29.2%. Patients received VBT alone (43.2%, n = 479), EBRT alone (14.3%, n = 158), EBRT+VBT (42.5%, n = 471), and chemotherapy (22.9%, n = 235). In HR and HIR groups, the proportion of VBT alone increased 33.3% (0 vs. 33.3%) and the proportion of VBT boost after EBRT decreased 10.5% (61.3% vs. 50.8%) from 2000 to 2015. In IR and LR groups, VBT alone increased 61.7% (4.7% vs. 66.4%) and VBT boost decreased 29.4% (51.6% vs. 22.2%) in the corresponding period. All institutions commonly use High-dose-rate(HDR) VBT. The commonly used applicators include the multichannel vaginal cylinder (77.7%), single channel vaginal cylinder (16.7%) and ovoids (5.6%). A fixed 3-4cm length of the proximal vagina was reported by 62.9%, a proximal 1/3-1/2 length of the vagina by 36.2%, and Entire vagina by 0.8%. Specify dose: 77.7% specify to 0.5-cm depth from the vaginal surface, and 22.3% specify elsewhere. There were 11 and 13 different dose-fractionation schedules for VBT alone and VBT boost, respectively. The most common fractionation for VBT alone and VBT boost is 5 Gy for six fractions and 5 Gy for two fractions, both to 0.5-cm depth. Our study provides an assessment of clinical practice pattern for adjuvant VBT management of early-stage EC in China. Historical data demonstrate that the clinical practice of adjuvant VBT alone increased significantly in different risk classification groups over the past 15 years, especially in IR to HR groups.

Preliminary results of adjuvant image-guided vaginal brachytherapy alone for early stage endometrial carcinoma

Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes

Impact of Different Adjuvant Radiotherapy Modalities on Women with Early-Stage Intermediate- to High-Risk Endometrial Cancer.

Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics

Vaginal brachytherapy management of stage I and II endometrial cancer

Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis

Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China

Clinical Practice Pattern Of Adjuvant Vaginal Brachytherapy In Early-Stage Endometrial Carcinoma According To Esmo-Esgo-Estro Risk Classification: Long-Term Updated Data From A Multi-Institutional Analysis In China

Clinical outcomes after salvage external beam radiotherapy combined with interstitial brachytherapy for locally advanced, recurrent endometrial cancer

Benefits Of Brachytherapy In Addition To External Beam Radiation In Early-Stage Endometrial Carcinoma: Analysis From A Multicenter Study

Treatment outcomes of early‐stage endometrial cancer patients: A propensity score matching of vaginal brachytherapy versus pelvic radiotherapy

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Outcomes of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer

External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis

Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion

Outcome and toxicity of chemoradiation using volumetric modulated arc therapy followed by 3D image-guided brachytherapy for cervical cancer: Vietnam National Cancer Hospital experience

EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates

Intra-cavitary brachytherapy in endometrial carcinoma: experience with cobalt-60 source

Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status

Retrospective Analysis of All Types of Adjuvant Radiotherapy in Endometrial Cancer: Single-Center Experiences in a Middle-Income Country

Single Application Multifractionated Image Guided Adaptive High-Dose-Rate Brachytherapy for Cervical Cancer: Dosimetric and Clinical Outcomes